IMV

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a
clinical stage vaccine company, today announced positive interim results from
the Company's Phase I clinical trial of DPX-Survivac, an ovarian cancer vaccine
candidate. The ongoing Phase I study is evaluating the potency, safety and
tolerability of DPX-Survivac alone or in combination with low dose oral
cyclophosphamide. Interim results showed that, to date, all nine patients
receiving DPX-Survivac in combination with cyclophosphamide produced a targeted
immune response following only one or two vaccine administrations. Patients
receiving a higher dose (0.5 mL) of DPX-Survivac in combination with
cyclophosphamide (n=3) produced immune responses after only one vaccination and
generally exhibited higher antigen specific immunity than those receiving the
combination with a lower (0.1 mL) DPX-Survivac dose (n=6), suggesting
dose-related activity. Importantly, patients in the two cohorts experienced
consistent immune responses that were detected at two consecutive time points.
Specifically, the first three patients enrolled in the 0.5 mL dose cohort in
combination with low dose cyclophosphamide demonstrated an average stimulation
factor of 350 times (350x) following the second vaccination, and in one patient
greater than 850 times (850x), over baseline responses. 


Additional results from the interim analysis showed that patients receiving
DPX-Survivac without cyclophosphamide were capable of producing antigen specific
immune responses. The interim analysis also showed the vaccine to be safe and
well tolerated with no systemic side-effects or dose limiting toxicities
reported to date. Adverse events were limited to expected local reactions at the
site of vaccination. Final results from the study, including a more extensive
safety and immunogenicity analysis of all cohorts, are expected by the end of
the year.


"These interim results provide important support for the ongoing DPX-Survivac
development program as they clearly demonstrate that the vaccine can activate
the desired immunity in our target patient population," said Marc Mansour, chief
science officer of Immunovaccine. "This offers further support of the
fundamental advantages and potential of our DepoVax platform as a powerful
vaccine adjuvanting technology." 


The ongoing Phase I DPX-Survivac trial is a multi-center, open-label,
dose-ranging study in previously diagnosed ovarian cancer patients who have been
treated by surgery and chemotherapy. Under the study protocol, these patients
each receive a total of three DPX-Survivac vaccinations three weeks apart. A
lead-in cohort of three patients received DPX-Survivac alone. Two additional
cohorts of six patients each received a low dose or a high dose of vaccine
concurrent with a low dose of oral cyclophosphamide. The trial's primary
objective is to evaluate the safety of the vaccine with and without the presence
of metronomic cyclophosphamide as an immune modulator. A secondary endpoint is
the evaluation of the immune response produced by the vaccine therapy. 


Immunovaccine has already received clearance from U.S. FDA and Health Canada for
the initiation of a Phase II trial of DPX-Survivac immediately following the
completion of the ongoing Phase I study. The Phase II trial will be a
randomized, double-blinded, placebo-controlled study with a single vaccine dose
selected based on the Phase I results. The Phase II trial will assess the
clinical benefit of DPX-Survivac in patients with advanced ovarian cancer.


About DPX-Survivac 

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in multiple cancer types in addition to ovarian cancer, including
breast, colon and lung cancers. Survivin plays an essential role in antagonizing
apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to
various anti-cancer therapies. Survivin is also a prognostic factor for many
cancers and it is found in a higher percentage of tumors than other TAA's.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
and specifically search for and destroy tumor cells. Survivin-specific T-cells
have been shown to target and kill survivin-expressing cancer cells while
sparing normal cells.


About DepoVax 

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine 

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release.

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024